Effect of FK506 on rat Leydig cell function—In vivo and in vitro study

FK506, a macrolide antibiotic, is a potent immunosuppressant and has a biological effect similar to that of cyclosporin A (CsA). In this study, the in vivo and in vitro effects of FK506 on rat Leydig cell function were investigated. In vivo, basal testosterone levels and secretion in response to human chorionic gonadotropin (hCG) stimulation in ACI rats treated with intramuscular (IM) injections of FK506 at a dosage of 1 or 2 mg/kg/d for 14 days were not different from those of age-matched normal controls. Testicular weights (g) from rats treated with 14 injections of 1 mg/kg/d FK506 (1.08 ± 0.08, n = 14) were similar to weights from age-matched controls (1.04 ± 0.08, n = 14). Similarly, Wistar (Wi) rats treated with FK506 at a dosage of 1 mg/kg/d for 2 weeks showed basal testosterone and luteinizing hormone (LH) levels and secretion in response to hCG stimulation similar to those of normal controls. Histologically, the Leydig cells and germ cells in FK506-treated animals appeared normal. In vitro, basal testosterone production and response to hCG stimulation by both ACI and Wi rat Leydig cells exposed to overnight treatment of FK506 (10 to 1,000 ng/mL) were not significantly different from those of control Leydig cells. Furthermore, the viability of the Leydig cells cultured for 3 days in FK506 was not significantly differnt from that of controls, and they continued to secrete testosterone at a rate similar to that of controls. In conclusion, results of the present study would indicate that FK506 at the dosages tested has no adverse effect on the function and morphology of rat Leydig cells both in vivo and in vitro.